Paclitaxel as Neoadjuvant Therapy for High Grade Angiosarcoma of the Spleen: A Brief Report and Literature Review

Vakkalanka, Bhanu; Milhem, Mohammed

doi:10.4137/cmo.s5329

Cited by 22 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,16 On immunohistochemistry, neoplastic cells express Factor VIII-associated antigen and 2 or more markers of vascular differentiation such as CD34, CD31 and VEGFR3. 4,5,10,11 CD68 and lysozyme, known as histiocytic differentiation markers are often also expressed. 5 Angiosarcomas tend to display complex karyotypes and no consistent recurrent chromosomal abnormalities have been found.…”

Section: Discussionmentioning

confidence: 99%

“…8,10 The main drug groups used are anthracyclines, ifosfamide and tax-anes. 11 Therapeutic responses to liposomal doxorubicin have also been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Some case-reports have reported potential benefit from systemic therapy in splenic angiosarcoma, in terms of down staging tumours and possibly improving outcome. 1,10 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Systemic therapy in primary angiosarcoma of the spleen

et al. 2012

View full text Add to dashboard Cite

Primary splenic angiosarcoma is a very rare neoplasm with a high propensity for metastatic disease and poor prognosis. There is a paucity of literature concerning this specific sarcoma subtype and the role of systemic therapy is not well defined. A retrospective review of the prospectively maintained University of Washington/Seattle Cancer Care Alliance Sarcoma Unit database was performed to identify patients with splenic angiosarcoma treated between 2007 and 2012. In total there were 19 patients with angiosarcoma treated at the Seattle Cancer Care Alliance from 2007 to 2012. The number of patients with splenic angiosarcoma was 2 (11%). The first patient was a woman aged 57 years who was referred with metastatic splenic angiosarcoma to the liver, post-splenectomy. She was treated with 4 cycles of weekly paclitaxel prior to metastatic resection and 4 cycles of the same drug in an adjuvant scenario, achieving a pathological complete response to treatment. She is alive and on third-line systemic therapy. The second patient was a male patient aged 30 years who presented with metastatic high-grade splenic angiosarcoma and was treated with 3 lines of systemic therapy, including doxorubicin, paclitaxel and gemcitabine+docetaxel, but developed a gastrointestinal metastasis with subsequent gastrointestinal bleeding. Splenic angiosarcoma is a very rare neoplasm. Surgery remains the mainstay of management for localized disease. Paclitaxel administered weekly proved to be well-tolerated and resulted in a good radiological response in one of our patients, enabling resection of metastatic disease. Durable clinical benefit can be achieved in metastatic splenic angiosarcoma with multi modality management.

show abstract

Section: Discussionmentioning

confidence: 99%

“…8,10 The main drug groups used are anthracyclines, ifosfamide and tax-anes. 11 Therapeutic responses to liposomal doxorubicin have also been reported.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic therapy in primary angiosarcoma of the spleen

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Paclitaxel use had already been reported as an adjuvant and neoadjuvant therapy by Vakkalanka and Milhem [24], suggesting that the unresectable tumor became resectable, thus improving survival with postoperative therapy. Our patient remained disease free for 1 year and 2 months after paclitaxel adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Splenic Angiosarcoma: A Diagnostic Splenectomy Finding

Azevedo

Santos²,

Liboni

et al. 2016

Case Rep Oncol

View full text Add to dashboard Cite

Splenic tumors are not frequent. Blood vessel neoplasms are a rare category of tumors and have an extremely low incidence in the spleen. This case report aims to describe a 57-year-old woman in whom a routine imaging examination had shown splenic cysts. During her follow-up, the cysts became larger and increased in number. A diagnostic splenectomy was performed and its analysis showed a rare splenic angiosarcoma.

show abstract

“…In comparison to spontaneous tumors that have a median survival expectation of nearly 9 months, radiation induced AS are more resistant to paclitaxel treatment and have a median overall survival of less than 6 months (Penel et al 2008). Paclitaxel has also been used as a neoadjuvant therapy to decrease primary tumor size prior to surgery for splenic AS (Vakkalanka & Milhem 2010).…”

Section: Prognosis and Treatmentmentioning

confidence: 99%